Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Jun Araki, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji Ichiro Sasaki

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalLung Cancer
Volume48
Issue number1
DOIs
Publication statusPublished - Apr 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer'. Together they form a unique fingerprint.

Cite this